| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 86.82 | 1-year : | 89.7 |
| Resists | First : | 74.33 | Second : | 76.8 |
| Pivot price | 73.38  |
|||
| Supports | First : | 70.36 | Second : | 58.53 |
| MAs | MA(5) : | 71.55 |
MA(20) : | 73.69 |
| MA(100) : | 69.34 |
MA(250) : | 61.82 |
|
| MACD | MACD : | -0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 9.2 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 76.8 | Low : | 48.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MTX ] has closed above bottom band by 15.1%. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 72.2 - 72.55 | 72.55 - 72.85 |
| Low: | 69.95 - 70.36 | 70.36 - 70.71 |
| Close: | 70.55 - 71.17 | 71.17 - 71.71 |
Tue, 09 May 2023
Researchers Are Mapping DMT Dimensions Through DMTx Tech - Psychedelic Spotlight
Tue, 10 Jan 2023
DMTx: Psychonauts Training Program to Explore Another Dimension - Sociedelic
Tue, 03 Oct 2017
Ultragenyx to Acquire Dimension Therapeutics - GlobeNewswire
Tue, 05 Sep 2017
OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors - PR Newswire
Tue, 27 Jun 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities - GlobeNewswire
Wed, 03 Aug 2016
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 32 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 98.8 (%) |
| Shares Short | 260 (K) |
| Shares Short P.Month | 340 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 50.97 |
| Profit Margin | 3.8 % |
| Operating Margin | 13.1 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 5.3 % |
| Qtrly Rev. Growth | 3.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 67.18 |
| EBITDA (p.s.) | 11.6 |
| Qtrly Earnings Growth | 100.5 % |
| Operating Cash Flow | 234 (M) |
| Levered Free Cash Flow | 174 (M) |
| PE Ratio | 27.57 |
| PEG Ratio | 2.2 |
| Price to Book value | 1.39 |
| Price to Sales | 1.05 |
| Price to Cash Flow | 9.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|